Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CV THERAPEUTICS INC (CVTX)
|
Add to portfolio |
|
|
|
| Price: |
$15.56
| | Metrics |
| OS: |
64.2
|
M
| |
|
|
| Market cap: |
$999
|
M
| |
-46
|
% ROIC
|
|
Net debt:
|
$28.9
|
M
| |
|
|
|
EV:
|
$1.03
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($82.1)
|
M
| |
|
|
|
EBIT
|
($82.1)
|
M
| |
|
|
| EPS |
($942.24)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 | Dec-31-01 |
| Revenues | 154.5 | 82.8 | 36.8 | 19.0 | 20.4 | 80.8 | 91.0 | 73.4 |
| Revenue growth | 86.5% | 125.2% | 94.1% | -7.2% | -74.7% | -11.2% | 23.9% | 101.3% |
| Cost of goods sold | 19.3 | 9.7 | 2.8 | 128.5 | 124.3 | 40.5 | 27.2 | 21.5 |
| Gross profit | 135.1 | 73.1 | 34.0 | -109.5 | -103.9 | 40.3 | 63.7 | 51.9 |
| Gross margin | 87.5% | 88.3% | 92.5% | -577.8% | -508.7% | 49.9% | 70.1% | 70.7% |
| Selling, general and administrative | 142.1 | 152.5 | 177.3 | 114.5 | 43.0 | 40.5 | | |
| Sales and marketing | | | | | | | 11.3 | 7.8 |
| General and administrative | | | | | | | 16.0 | 13.8 |
| EBIT | -82.1 | -174.1 | -278.5 | -224.0 | -146.9 | -110.0 | -112.9 | -88.2 |
| EBIT margin | -53.1% | -210.2% | -757.1% | -1182.2% | -719.2% | -136.1% | -124.1% | -120.1% |
| Pre-tax income | -91.4 | -181.0 | -274.3 | -228.0 | -155.1 | -111.0 | -107.8 | -79.7 |
| Income taxes | 7.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -98.5 | -181.0 | -274.3 | -228.0 | -155.1 | -111.0 | -107.8 | -79.7 |
| Net margin | -63.8% | -218.5% | -745.7% | -1203.1% | -759.2% | -137.3% | -118.5% | -108.5% |
| |
| Diluted EPS | ($1.61) | ($3.05) | ($5.49) | ($5,661.94) | ($4.90) | ($3,912.24) | ($4,130.34) | ($3.74) |
| Shares outstanding (diluted) | 61.1 | 59.3 | 50.0 | 0.0 | 31.7 | 0.0 | 0.0 | 21.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|